No headlines found.
Globe Newswire (Fri, 22-Mar 4:05 PM ET)
Globe Newswire (Thu, 22-Feb 8:00 AM ET)
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Salarius Pharmaceuticals trades on the NASDAQ stock market under the symbol SLRX.
As of May 2, 2024, SLRX stock price declined to $0.53 with 83,965 million shares trading.
SLRX has a beta of -0.44, meaning it tends to be less sensitive to market movements. SLRX has a correlation of 0.01 to the broad based SPY ETF.
SLRX has a market cap of $2.52 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SLRX stock traded as high as $37.75 and as low as $.43.
The top ETF exchange traded funds that SLRX belongs to (by Net Assets): MEDX, VXF.
SLRX has underperformed the market in the last year with a return of -70.5%, while the SPY ETF gained +23.2%. In the last 3 month period, SLRX fell short of the market, returning -5.6%, while SPY returned +3.6%. However, in the most recent 2 weeks SLRX has outperformed the stock market by returning +3.3%, while SPY returned +0.9%.
SLRX support price is $.50 and resistance is $.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLRX stock will trade within this expected range on the day.